Compare MDWD & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDWD | IDR |
|---|---|---|
| Founded | 2000 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.5M | 378.0M |
| IPO Year | 2014 | N/A |
| Metric | MDWD | IDR |
|---|---|---|
| Price | $18.72 | $45.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $37.50 | $17.50 |
| AVG Volume (30 Days) | 82.4K | ★ 536.1K |
| Earning Date | 11-20-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.70 |
| EPS | N/A | ★ 0.73 |
| Revenue | $20,932,000.00 | ★ $35,424,313.00 |
| Revenue This Year | $15.89 | $55.62 |
| Revenue Next Year | $25.33 | $23.93 |
| P/E Ratio | ★ N/A | $62.44 |
| Revenue Growth | 6.15 | ★ 61.35 |
| 52 Week Low | $14.14 | $9.67 |
| 52 Week High | $22.51 | $54.70 |
| Indicator | MDWD | IDR |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 61.69 |
| Support Level | $18.55 | $41.65 |
| Resistance Level | $18.96 | $49.42 |
| Average True Range (ATR) | 0.57 | 3.38 |
| MACD | 0.01 | 0.36 |
| Stochastic Oscillator | 55.79 | 72.34 |
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.